Search

Your search keyword '"Morgana Ohira Gazzeta"' showing total 11 results
Start Over Author "Morgana Ohira Gazzeta"
11 results on '"Morgana Ohira Gazzeta"'

1. To be or not to B27 positive: implications for the phenotypes of axial spondyloarthritis outcomes. Data from a large multiracial cohort from the Brazilian Registry of Spondyloarthritis

Author

Gustavo Gomes Resende, Carla Goncalves Schahin Saad, Claudia Diniz Lopes Marques, Sandra Lúcia Euzébio Ribeiro, Maria Bernadete Renoldi de Oliveira Gavi, Michel Alexandre Yazbek, Adriana de Oliveira Marinho, Rita de Cássia Menin, Manuella Lima Gomes Ochtrop, Andressa Miozzo Soares, Nara Gualberto Cavalcanti, Jamille Nascimento Carneiro, Glaucio Ricardo Werner de Castro, José Mauro Carneiro Fernandes, Elziane da Cruz Ribeiro E Souza, Corina Quental de Menezes Alvarenga, Rejane Maria Rodrigues de Abreu Vieira, Natalia Pereira Machado, Antônio Carlos Ximenes, Morgana Ohira Gazzeta, Cleandro Pires de Albuquerque, Thelma Larocca Skare, Mauro Waldemar Keiserman, Charles Lubianca Kohem, Gabriel Sarkis Benacon, Vítor Florêncio Santos Rocha, Ricardo da Cruz Lage, Olivio Brito Malheiro, Rywka Tenenbaum Medeiros Golebiovski, Thauana Luiza Oliveira, Ruben Horst Duque, Ana Carolina Londe, Marcelo de Medeiros Pinheiro, and Percival Degrava Sampaio-Barros

Subjects
Axial spondyloarthritis, HLA-B27, Genetics, Register-study, ASDAS-CRP, Ankylosing spondylitis, Diseases of the musculoskeletal system, RC925-935, Immunologic diseases. Allergy, RC581-607
Abstract

Abstract Background There is a remarkable variability in the frequency of HLA-B27 positivity in patients with spondyloarthritis (SpA), which may be associated with different clinical presentations worldwide. However, there is a lack of data considering ethnicity and sex on the evaluation of the main clinical and prognostic outcomes in mixed-race populations. The aim of this study was to evaluate the frequency of HLA-B27 and its correlation with disease parameters in a large population of patients from the Brazilian Registry of Spondyloarthritis (RBE). Methods The RBE is a multicenter, observational, prospective cohort that enrolled patients with SpA from 46 centers representing all five geographic regions of Brazil. The inclusion criteria were as follow: (1) diagnosis of axSpA by an expert rheumatologist; (2) age ≥18 years; (3) classification according to ASAS axial. The following data were collected via a standardized protocol: demographic data, disease parameters and treatment historical. Results A total of 1096 patients were included, with 73.4% HLA-B27 positivity and a mean age of 44.4 (±13.2) years. Positive HLA-B27 was significantly associated with male sex, earlier age at disease onset and diagnosis, uveitis, and family history of SpA. Conversely, negative HLA-B27 was associated with psoriasis, higher peripheral involvement and disease activity, worse quality of life and mobility. Conclusions Our data showed that HLA-B27 positivity was associated with a classic axSpA pattern quite similar to that of Caucasian axSpA patients around the world. Furthermore, its absence was associated with peripheral manifestations and worse outcomes, suggesting a relevant phenotypic difference in a highly miscegenated population.

Published
2024
Full Text
View/download PDF

4. Epidemiologic Features of Systemic Vasculitides in the Southeast Region of Brazil

Author

Jozelia Rêgo, Roger A. Levy, Gilda Aparecida Ferreira, Valquiria Garcia Dinis, Bruno Schau, Alexandre Wagner Silva de Souza, Ana Luisa Calich, Mittermayer Barreto Santiago, Joice Moraes F M Belem, Morgana Ohira Gazzeta, Manuella Lima Gomes Ochtrop, Ana Beatriz Santos Bacchiega, Ana Luisa Pedreira, Henrique de Ataíde Mariz, Ruben Horst Duque, Rosa Maria Rodrigues Pereira, Mariana O. Perez, Zoraida Sachetto, Célio Roberto Gonçalves, Fabrícia Fonseca Simil, and Leandro Lara do Prado

Subjects
medicine.medical_specialty, Adolescent, business.industry, Polyarteritis nodosa, Granulomatosis with Polyangiitis, Churg-Strauss Syndrome, medicine.disease, Dermatology, Hospitals, Giant cell arteritis, Cross-Sectional Studies, Rheumatology, medicine, Humans, Outpatient clinic, Child, business, Microscopic polyangiitis, Vasculitis, Granulomatosis with polyangiitis, Cryoglobulinemic vasculitis, Brazil, Systemic vasculitis
Abstract

Background/objective The epidemiology of vasculitis is variable in different geographic areas, and this issue has not been approached in Brazil yet. The objective of this study was to assess the frequency of vasculitis in specialized centers in Brazil. Methods This cross-sectional study was performed in 9 vasculitis outpatient clinics from 6 different states mainly from the Southeast and the Northeast regions of Brazil between 2015 and 2017. Diagnosis and/or classification criteria for Behcet disease (BD), Takayasu arteritis (TA), giant cell arteritis (GCA), polyarteritis nodosa (PAN), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA), and cryoglobulinemic vasculitis (CryoVas) were used to include patients with at least 6 months of follow-up in this hospital-based survey. Results A total of 1233 patients with systemic vasculitis were included from the Southeast region. Behcet disease was the most frequent vasculitis (35.0%) followed by TA (26.4%), GPA (16.2%), PAN (5.8%), GCA (5.8%), EGPA (4.3%), MPA (3.4%), and CryoVas (3.0%). Up to 7.8% of vasculitis patients had a juvenile onset, and the frequency of vasculitides found in children and adolescents was as follows: TA (52.6%), BD (24.7%), GPA (12.4%), and PAN (10.3%). No cases of EGPA, MPA, and CryoVas were diagnosed before the age of 18 years. As a comparator, 103 vasculitis patients were included in the Northeast of Brazil where TA was found in 36.9% and BD in 31.1% of vasculitis cases. No GCA cases were found in the Northeast part of Brazil. Conclusions Similar to the epidemiology of vasculitis in Asia, BD and TA are the most frequent vasculitis in Southeastern Brazilian referral centers.

Published
2019
Full Text
View/download PDF

5. BIOBADABRASIL: SAFETY PROFILE OF THE FIRST BIOLOGICAL AGENT OR JAK INHIBITOR FOR THE TREATMENT OF RA

Author

Ivanio Alves Pereira, Jose Roberto Prevenza, Manoel Barros Bertolo, Claiton Viegas Brenol, Adriana Maria Kakehasi, Hellen M.S. Carvalho, Jose Carlos Amaral, Barbara Standler Kahlow, Laurindo Ferreira da Rocha, José Caetano Macieira, David C. Titton, Roberto Ranza, Rina Dalva Neubarth Giorgi, Aline Ranzolin, Geraldo da Rocha Castelar Pinheiro, Flavio Sztajnbok, Paulo Lozada, Deborah Negrão Gonçalo Dias, Morton Scheinberg, Reginaldo Botelho Teodoro, Markus Bredmeir, André Luiz Shinji Hayata, Helena Lúcia Alves Pereira, Angela Luzia Branco Pinto Duarte, Vander Fernandes, Ieda Maria Magalhães Laurindo, Ana Cristina de Medeiros Ribeiro, José Roberto Silva Miranda, Morgana Ohira Gazzeta, Marcelo De Medeiro Pinheiro, Maria de Fátima Lobato da Cunha Sauma, Cristiano Michelini Lupo, S. Studart, Valéria Valim Cristo, Inês Guimarães da Silveira, Gláucio Ricardo Werner de Castro, and Sergio Kowalski

Subjects
Safety profile, business.industry, Medicine, Pharmacology, business
Published
2021
Full Text
View/download PDF

6. SURVIVAL OF THE FIRST ANTI-TNF IN YOUNGER AND ELDERLY RHEUMATOID ARTHRITIS PATIENTS FROM BIOBADABRASIL REGISTRY

Author

José Caetano Macieira, Marcelo de Medeiros Pinheiro, Roberto Ranza, Laurindo Ferreira da Rocha, Aline Ranzolin, Ivânio Alves Pereira, Sergio Kowalski, Fabiana Pompeo de Pina, Ângela Luzia Branco Pinto Duarte, Bárbara Stadler Kahlow, Markus Bredemeier, Cristiano Michelini Lupo, Deborah Negrão Gonçalo Dias, Maria de Fátima Lobato da Cunha Sauma, Paulo Louzada-Junior, Morgana Ohira Gazzeta, Rafael Mendonça Silva da Chakr, Reginaldo Botelho Teodoro, Adriana Maria Kakehasi, Ieda Maria Magalhães Laurindo, Gláucio Ricardo Werner de Castro, Samia Araujo de Souza Studart, Vander Fernandes, Manoel Barros Bertolo, Claiton Viegas Brenol, José Roberto Silva Miranda, Ana Cristina de Medeiros Ribeiro, D. Titton, Geraldo da Rocha Castelar Pinheiro, Hellen M.S. Carvalho, Inês Guimarães da Silveira, Valéria Valim Cristo, Lidia Balarini, Ricardo Machado Xavier, and André Luiz Shinji Hayata

Subjects
medicine.medical_specialty, business.industry, Rheumatoid arthritis, Internal medicine, Medicine, Tumor necrosis factor alpha, business, medicine.disease
Published
2021
Full Text
View/download PDF

7. Safety of the Methotrexate–leflunomide Combination in Rheumatoid Arthritis: Results of a Multicentric, Registry-based, Cohort Study (BiobadaBrasil)

Author

José Caetano Macieira, André Luiz Shinji Hayata, Ana Cristina de Medeiros Ribeiro, Paulo Roberto Louzada, Reginaldo Botelho Teodoro, Vander Fernandes, Hellen M.S. Carvalho, Manoel Barros Bertolo, Ângela Luzia Branco Pinto Duarte, Marcelo de Medeiros Pinheiro, Roberto Ranza, Adriana Maria Kakehasi, Bárbara Stadler Kahlow, Ivânio Alves Pereira, Aline Ranzolin, Markus Bredemeier, Cristiano Michelini Lupo, Maria de Fátima Lobato da Cunha Sauma, Laurindo Ferreira da Rocha, Letícia Guimarães da Silveira, David C. Titton, Gláucio Ricardo Werner de Castro, Ieda Maria Magalhães Laurindo, Morgana Ohira Gazzeta, Valeria Valim, Inês Guimarães da Silveira, S. Studart, Geraldo da Rocha Castelar Pinheiro, and José Roberto Silva Miranda

Subjects
Oncology, medicine.medical_specialty, Immunology, Arthritis, Rheumatoid, Cohort Studies, Rheumatology, Sulfasalazine, Internal medicine, Medicine, Humans, Immunology and Allergy, Registries, Adverse effect, Leflunomide, business.industry, Proportional hazards model, Incidence (epidemiology), Isoxazoles, medicine.disease, Methotrexate, Rheumatoid arthritis, Drug Therapy, Combination, business, medicine.drug, Cohort study
Abstract

Objective.To evaluate the safety of the methotrexate (MTX)–leflunomide (LEF) combination in rheumatoid arthritis (RA), comparing it with other therapeutic schemes involving conventional synthetic (cs-) and biologic (b-) disease-modifying antirheumatic drugs (DMARDs) or Janus kinase inhibitors (JAKi).Methods.Patients with RA starting a treatment course with a csDMARD (without previous use of bDMARD or JAKi) or their first bDMARD/JAKi were followed up in a registry-based, multicentric cohort study in Brazil (BiobadaBrasil). The primary outcome was the incidence of serious adverse events (SAEs); secondary outcomes included serious infections. Multivariate Cox proportional hazards models and propensity score matching analysis (PSMA) were used for statistical comparisons.Results.In total, 1671 patients (5349 patient-years [PY]) were enrolled; 452 patients (1537 PY) received MTX + LEF. The overall incidence of SAEs was 5.6 per 100 PY. The hazard of SAEs for MTX + LEF was not higher than for MTX or LEF (adjusted HR [aHR] 1.00, 95% CI 0.76–1.31, P = 0.98). MTX + LEF presented a lower hazard of SAEs (aHR 0.56, 95% CI 0.36–0.88, P = 0.01) and infectious SAEs (aHR 0.48, 95% CI 0.25–0.94, P = 0.03) than bDMARDs/JAKi with MTX or LEF. MTX + LEF presented lower hazard of SAEs than MTX + sulfasalazine (SSZ; aHR 0.33, 95% CI 0.16–0.65, P = 0.002). Analysis using PSMA confirmed the results obtained with traditional multivariate Cox analysis.Conclusion.In our study, MTX + LEF presented a relatively good overall safety profile in comparison to MTX + SSZ and schemes involving advanced therapies in RA.

Published
2022
Full Text
View/download PDF

8. RISK FOR TUBERCULOSIS DURING TREATMENT WITH BIOLOGICAL THERAPY: IS IT TIME FOR REVIEWING SCREENING PROTOCOL? – RESULTS FROM BRAZILIAN REGISTRY OF BIOLOGICAL THERAPIES IN RHEUMATIC DISEASES (BIOBADABRASIL)

Author

Daniel Feldman, Aline Ranzolin, A Acayaba, Gláucio Ricardo Werner de Castro, José Roberto Provenza, Markus Bredemeier, R Botelho, Jorge Miguel Miranda, Laurindo Ferreira da Rocha, Lidiane Oliveira de Carvalho, D. Titton, A Medeiros Ribeiro, Washington A. Bianchi, G. Castelar, Angela Luzia Branco Pinto Duarte, Vander Fernandes, Hellen M.S. Carvalho, André Luiz Shinji Hayata, M.L. Pinheiro, Roberto Ranza, C Macieira, Ieda Maria Magalhães Laurindo, Ivânio Alves Pereira, Manoel Barros Bertolo, Claiton Viegas Brenol, Morgana Ohira Gazzeta, Valeria Valim, Joana S. Amaral, S. Studart, Inês Guimarães da Silveira, S Schowalski, Paulo Roberto Louzada, F Sauma, B. Stadler, Adriana Maria Kakehasi, and H. Resende

Subjects
Protocol (science), medicine.medical_specialty, Biological therapies, Tuberculosis, business.industry, Medicine, business, Intensive care medicine, medicine.disease
Published
2019
Full Text
View/download PDF

9. THE EXPERIENCE OF TOCILIZUMAB IN PATIENTS WITH A DIAGNOSIS OF RHEUMATOID ARTHRITS AT THE RHEUMATOLOGY´S DEPARTMENT OF HOSPITAL SANTA CASA DE MISERICORDIA DO RIO DE JANEIRO (HSCMRJ)

Author

Camila Mamede Ferraço, Raíssa Guimarães Canellas Oliveira, Washington Alves Bianchi, Morgana Ohira Gazzeta, Dante Valdetaro Bianchi, Lucas Borges Figueiredo Chicre Costa, Taiane Palácio Bomfim, and Breno Valdetaro Bianchi

Subjects
medicine.medical_specialty, chemistry.chemical_compound, Tocilizumab, chemistry, business.industry, General surgery, Internal medicine, medicine, In patient, business, Rheumatology
Published
2019
Full Text
View/download PDF

10. SAFETY OF THE METHOTREXATE-LEFLUNOMIDE COMBINATION IN THE BRAZILIAN REGISTRY OF BIOLOGICAL THERAPIES IN RHEUMATIC DISEASES (BIOBADABRASIL)

Author

Valéria Valim Cristo, Daniel Feldman Pollak, Sérgio Cândido Kowalski, Reginaldo Botelho Teodoro, Aline Ranzolin, Ivanio Alves Pereira, Jéssica Martins Amaral, Geraldo da Rocha Castelar Pinheiro, Vander Fernandes, José Caetano Macieira, Maria de Fátima Lobato da Cunha Sauma, Markus Bredemeier, Marcelo de Medeiros Pinheiro, Roberto Acayaba de Toledo, Hellen M.S. Carvalho, José Roberto Silva Miranda, Angela Luiza B P Duarte, Laurindo Ferreira da Rocha Junior, David Cesar Titon, Ana Cristina Medeiros-Ribeiro, Roberto Ranza, Bárbara Stadler Kahlow, Washington A. Bianchi, André Luiz Shinji Hayata, Inês Guimarães da Silveira, S. Studart, Morgana Ohira Gazzeta, Lina Oliveira de Carvalho, Manoel Barros Bertolo, Claiton Viegas Brenol, Gláucio Ricardo Werner de Castro, Ieda Maria Magalhães Laurindo, Adriana Maria Kakehasi, and Paulo Roberto Louzada

Subjects
Oncology, medicine.medical_specialty, Biological therapies, business.industry, Internal medicine, medicine, Methotrexate, business, medicine.drug, Leflunomide
Published
2019
Full Text
View/download PDF

11. Azathioprine as a steroid sparing agent in leprosy Type 2 reactions: Report of nine cases

Author

Simone de Abreu Neves Salles, Sandra Maria Barbosa Durães, Veronica Rodrigues Bogado Leite, and Morgana Ohira Gazzeta

Subjects
Adult, Male, medicine.medical_specialty, Treatment outcome, Leprostatic Agents, Leprostatic agent, Azathioprine, Young Adult, Erythema Nodosum, Prednisone, Steroid sparing, medicine, Humans, Glucocorticoids, General Environmental Science, Erythema nodosum, business.industry, Middle Aged, medicine.disease, Dermatology, Surgery, Leprosy, Lepromatous, Treatment Outcome, General Earth and Planetary Sciences, Female, Leprosy, business, Immunosuppressive Agents, medicine.drug
Abstract

SANDRA MARIA BARBOSA DURAES*, SIMONE DE ABREU NEVES SALLES**, VERONICA RODRIGUES BOGADO LEITE*** & MORGANA OHIRA GAZZETA**** *Adjunct Professor of Dermatology at Universidade Federal Fluminense, Rio de Janeiro, Brazil **Assistant Professor of Dermatology at Universidade Federal Fluminense, Rio de Janeiro, Brazil ***Graduate Student in Dermatology, Universidade Federal Fluminense, Rio de Janeiro, Brazil ****Medical student at Universidade Federal Fluminense, Rio de Janeiro, Brazil

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results